-
Je něco špatně v tomto záznamu ?
Výsledky koronární angiografie ve studii ASTEROID
[Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden]
Christie M. Ballantyne, et al.
Jazyk čeština Země Česko
- MeSH
- fluorbenzeny aplikace a dávkování farmakologie MeSH
- intervenční ultrasonografie MeSH
- koronární angiografie metody MeSH
- koronární stenóza diagnóza farmakoterapie MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nemoci koronárních tepen farmakoterapie ultrasonografie MeSH
- pyrimidiny aplikace a dávkování farmakologie MeSH
- senioři MeSH
- sulfonamidy aplikace a dávkování farmakologie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
Previous studies using quantitative coronary angiography have demonstrated that statin therapy slows the progression of coronary stenoses in proportion to average low-density lipoprotein cholesterol levels during therapy. However, no major statin monotherapy study has demonstrated either halted progression or regression of angiographic disease. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) assessed whether rosuvastatin could regress coronary atherosclerosis by intravascular ultrasound and quantitative coronary angiography. Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing. METHODS AND RESULTS: ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for 24 months. Blinded quantitative coronary angiography analyses of percent diameter stenosis and minimum lumen diameter were performed for up to 10 segments of coronary arteries and major branches with >25% diameter stenosis at baseline. For each patient, the mean of all matched lesions at baseline and study end was calculated. There were 292 patients with 613 matched stenoses. Rosuvastatin reduced low-density lipoprotein cholesterol by 53.3% to 61.1+/-20.3 mg/dL and increased high-density lipoprotein cholesterol by 13.8% to 48.3+/-12.4 mg/dL. Mean+/-SD percent diameter stenosis decreased from 37.3+/-8.4% (median, 35.7%; range, 26% to 73%) to 36.0+/-10.1% (median, 34.5%; range, 8% to 74%; P<0.001). Minimum lumen diameter increased from 1.65+/-0.36 mm (median, 1.62 mm; range, 0.56 to 2.65 mm) to 1.68+/-0.38 mm (median, 1.67 mm; range, 0.76 to 2.77 mm; P<0.001). CONCLUSIONS: Rosuvastatin treatment for 24 months to average low-density lipoprotein cholesterol levels well below 70 mg/dL, accompanied by significant increases in high-density lipoprotein cholesterol, produced regression by decreasing percent diameter stenosis and improving minimum lumen diameter as measured by quantitative coronary angiography in coronary disease patients.
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07521954
- 003
- CZ-PrNML
- 005
- 20111210133035.0
- 008
- 090423s2008 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Ballantyne, C. M. $q (Christie Mitchell), $d 1955- $7 nlk20040153184
- 245 10
- $a Výsledky koronární angiografie ve studii ASTEROID / $c Christie M. Ballantyne, et al.
- 246 11
- $a Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
- 314 __
- $a Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston
- 520 9_
- $a Previous studies using quantitative coronary angiography have demonstrated that statin therapy slows the progression of coronary stenoses in proportion to average low-density lipoprotein cholesterol levels during therapy. However, no major statin monotherapy study has demonstrated either halted progression or regression of angiographic disease. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) assessed whether rosuvastatin could regress coronary atherosclerosis by intravascular ultrasound and quantitative coronary angiography. Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing. METHODS AND RESULTS: ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for 24 months. Blinded quantitative coronary angiography analyses of percent diameter stenosis and minimum lumen diameter were performed for up to 10 segments of coronary arteries and major branches with >25% diameter stenosis at baseline. For each patient, the mean of all matched lesions at baseline and study end was calculated. There were 292 patients with 613 matched stenoses. Rosuvastatin reduced low-density lipoprotein cholesterol by 53.3% to 61.1+/-20.3 mg/dL and increased high-density lipoprotein cholesterol by 13.8% to 48.3+/-12.4 mg/dL. Mean+/-SD percent diameter stenosis decreased from 37.3+/-8.4% (median, 35.7%; range, 26% to 73%) to 36.0+/-10.1% (median, 34.5%; range, 8% to 74%; P<0.001). Minimum lumen diameter increased from 1.65+/-0.36 mm (median, 1.62 mm; range, 0.56 to 2.65 mm) to 1.68+/-0.38 mm (median, 1.67 mm; range, 0.76 to 2.77 mm; P<0.001). CONCLUSIONS: Rosuvastatin treatment for 24 months to average low-density lipoprotein cholesterol levels well below 70 mg/dL, accompanied by significant increases in high-density lipoprotein cholesterol, produced regression by decreasing percent diameter stenosis and improving minimum lumen diameter as measured by quantitative coronary angiography in coronary disease patients.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a koronární angiografie $x metody $7 D017023
- 650 _2
- $a nemoci koronárních tepen $x farmakoterapie $x ultrasonografie $7 D003324
- 650 _2
- $a koronární stenóza $x diagnóza $x farmakoterapie $7 D023921
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluorbenzeny $x aplikace a dávkování $x farmakologie $7 D005464
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pyrimidiny $x aplikace a dávkování $x farmakologie $7 D011743
- 650 _2
- $a sulfonamidy $x aplikace a dávkování $x farmakologie $7 D013449
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a intervenční ultrasonografie $7 D018084
- 650 _2
- $a lidé $7 D006801
- 773 0_
- $w MED00012706 $t Clinical cardiology alert $g Roč. 2, č. 5 (2008), s. 34-35 $x 1213-2586
- 787 18
- $w bmc07521957 $i Recenze v: $t Komentář [k článku Výsledky koronární angiografie ve studii ASTEROID]
- 910 __
- $a ABA008 $b B 2242 $c 407 a $y 9
- 990 __
- $a 20090423080915 $b ABA008
- 991 __
- $a 20090601112122 $b ABA008
- 999 __
- $a ok $b bmc $g 645043 $s 497959
- BAS __
- $a 3
- BMC __
- $a 2008 $b 2 $c 5 $d 34-35 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
- LZP __
- $a 2009-15/mkme